Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cinnamaldehyde is a naturally occurring small molecule and the primary constituent of cinnamon bark oil. It is widely recognized in pharmacology as a potent and selective agonist of the **Transient Receptor Potential Ankyrin 1 (TRPA1)** ion channel. In clinical research settings, such as those conducted by Aalborg University, cinnamaldehyde is utilized as an experimental pharmacological probe rather than a therapeutic agent. It is applied topically or intradermally to healthy volunteers to induce TRPA1-mediated sensory responses, including pain and non-histaminergic itch. This application serves to characterize sensory pathways and evaluate the efficacy of surrogate models, such as BAM8-22, in the study of chronic itch mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cinnamaldehyde (Aalborg University).